Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease

Highlights • Integrin α4β7 is involved in T cell alloreactivity in acute graft-versus-host disease (GVHD) of the gut. • Vedolizumab, a monoclonal antibody, targets the homing of T cells to the intestinal endothelium through inhibition of binding of integrin α4β7. • Six patients were treated with ved...

Full description

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2017, Vol.23 (1), p.172-175
Main Authors: Fløisand, Yngvar, Lundin, Knut E.A, Lazarevic, Vladimir, Kristiansen, Jørn Dehli, Osnes, Liv T.N, Tjønnfjord, Geir E, Reims, Henrik Mikael, Gedde-Dahl, Tobias
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal, Humanized - therapeutic use
Female
Gastrointestinal Agents - therapeutic use
Graft vs Host Disease - drug therapy
Graft vs Host Disease - pathology
Graft-versus-host disease
Gut GVHD
Hematology, Oncology and Palliative Medicine
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Integrin
Integrins - drug effects
Intestinal Diseases - drug therapy
Male
Middle Aged
Salvage Therapy - methods
Stem cell transplant
Steroid refractory
Steroids - therapeutic use
Transplantation, Homologous
Treatment Outcome
Vedolizumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Integrin α4β7 is involved in T cell alloreactivity in acute graft-versus-host disease (GVHD) of the gut. • Vedolizumab, a monoclonal antibody, targets the homing of T cells to the intestinal endothelium through inhibition of binding of integrin α4β7. • Six patients were treated with vedolizumab for grade IV gut GVHD with clinical responses. • The findings presented in this case series give hope for novel therapy of steroid-refractory intestinal GVHD.
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2016.10.009